Research
Hormonal
NB-ER (naltrexone-bupropion extended-release) reduces food cravings and improves control over eating by acting on central hypothalamic and mesolimbic dopaminergic systems, distinct from the peripheral effects of gut hormone analogs.
NB-ER helps with weight loss by targeting the brain's reward system to reduce cravings and improve self-control, rather than just slowing digestion. It typically leads to 6-12% weight loss over a year, depending on whether you have diabetes.
GoodSupportsHIGH confidence
NB-ER increases the activity of norepinephrine and dopamine via the reuptake inhibitor bupropion to stimulate hypothalamic POMC cells and prevents the subsequent inhibition of these cells via the opioid antagonist naltrexone... acts via the hypothalamic and mesolimbic systems to reduce food intake and reward-based eating.
Why this rating
Supported by clinical trials and neuroimaging studies cited.
Source
Targeting Multiple Gut‐Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy
Alexander D. Miras et al. · Obesity Science & Practice · 2026
DOI 10.1002/osp4.70141
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Combining gut hormone analog medications (e.g., GLP-1/GIP agonists) with naltrexone-bupropion extended-release (NB-ER) provides a mechanistic rationale for improved weight loss in patients who fail to achieve goals with monotherapy, by targeting distinct satiety and reward pathways.Good
- Gut hormone analog medications (liraglutide, semaglutide, tirzepatide) reduce energy intake and alter food preferences primarily through delayed gastric emptying and hypothalamic/brainstem satiety signaling, rather than direct effects on reward centers.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →